DGAP-News: AiCuris Anti-infective Cures GmbH / Key word(s): Study/Study results AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study 23.08.2016 / 09:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study Wuppertal, August 23rd, 2016 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that pritelivir (one of its lead compounds), a small molecule helicase-primase inhibitor active against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), achieved the primary endpoint in a phase I trial for topical treatment of recurrent labial herpes (cold sores). In this trial with healthy volunteers, pritelivir 5% ointment did not show any cumulative irritation potential. This phase I trial is part of a second development program for pritelivir, after it has already shown superiority against standard treatment valacyclovir in a clinical phase II trial in patients with genital HSV-2 infection with oral treatment. The randomized, single-center, controlled, within-subject comparison phase I trial (AIC316-02-I-01), conducted in the U.S., was designed to determine the local cumulative irritation potential of topical pritelivir on normal human skin in 46 male and female healthy volunteers under occlusive conditions. Each volunteer received daily pritelivir 5% ointment and in parallel three controls for 21 days on the back. The controls were: the vehicle ointment without pritelivir, saline as a negative control and 0.2% sodium lauryl sulfate (SLS) as a positive control. Application sites were assessed daily in a blinded manner by evaluators for dermal reactions using a visual skin irritation scoring system to rate the degree of erythema, edema and other signs of skin irritation. The trial showed that pritelivir 5% ointment had no cumulative irritation potential; as expected, the positive control SLS caused local irritation in all subjects. "These phase I results, coupled with the preclinical results we have seen with topical pritelivir, are highly promising and strongly support the further development of topical pritelivir for recurrent labial herpes," said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH. "There remains a major unmet medical need to treat HSV-1 infections, such as labial herpes, as there are very few specific antivirals available and available topical treatments are often ineffective. Topical pritelivir, if proven safe and effective in further clinical testing, could be an important new treatment option for this very painful condition. We are looking forward to continued progress with this innovative approach and expect to start a clinical phase II proof of concept study in the U.S. later this year." About Pritelivir Pritelivir is an innovative, highly active and specific inhibitor of herpes simplex virus (HSV). Derived from a novel chemical class (thiazolylamides), pritelivir is active against both types of herpes simplex virus (HSV-1 and HSV-2), causing labial and genital herpes, respectively, and retains activity against viruses which have become resistant to marketed drugs. Pritelivir has a mode of action that is distinct from other antiviral agents currently in use for treating HSV infections (i.e., the nucleoside analogues acyclovir and its prodrug valacyclovir as well as famciclovir, the prodrug of penciclovir). While nucleoside analogs terminate ongoing DNA chain elongation through inhibition of viral DNA polymerase, pritelivir prevents de novo synthesis of virus DNA through inhibition of the helicase- primase complex. In addition, it does not require activation within an HSV infected cell by viral thymidine kinase and is therefore also protective to uninfected cells. Currently the company runs two clinical development programs with pritelivir. The most advanced program, pritelivir (oral), showed superiority against standard treatment valacyclovir in a clinical phase II trial in patients with genital HSV-2 infection. Pritelivir (topical), designed for the treatment of recurrent labial herpes (mainly HSV-1), has reported successful phase I clinical results. About HSV Herpes simplex viruses (HSV) are widespread (seroprevalence up to 100%, depending on geographic area and subpopulation), and are divided into herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Infections lead to lifelong persistence of the virus, with frequent and sometimes painful recurrences. While HSV-1 predominantly causes oral lesions (cold sores), HSV-2 manifests in the genital region and is mainly sexually transmitted. In immunocompromised patients, HSV can lead to serious complications. The negative stigma associated with genital herpes and visible facial lesions may cause psychological distress. According to the WHO an estimated 3.7 billion people worldwide under the age of 50, or 67% of the population, were infected with HSV-1 in 2012. Prevalence of the infection was estimated highest in Africa (87%) and lowest in the Americas (40-50%). About AiCuris Anti-infective Cures GmbH AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs against infectious diseases. The company's majority investor is SANTO Holding. The company is developing drugs for the treatment of viruses such as human cytomegalovirus (HCMV), herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multi-resistant hospital-treated pathogens. In 2012, AiCuris signed a license agreement with Merck & Co (MSD), one of the largest agreements of its kind in the European biotech industry. The agreement covers the development of novel drug candidates against HCMV. Letermovir, the most advanced compound under this agreement, is currently in phase III clinical trials in patients undergoing bone marrow transplantation. Contact: <pre> Media Relations AiCuris Anti-infective Cures MC Services AG GmbH Katja Woestenhemke Anne Hennecke Friedrich-Ebert-Str. 475/Geb. Kaiser-Friedrich-Ring 5 302 42117 Wuppertal 40545 Düsseldorf Phone +49 202 317 63 0 Phone +49 211 529 252 22 Fax +49 202 317 63 1601 Fax +49 211 529 252 29 Email business@aicuris.com Email anne.hennecke@mc-services.eu Web www.aicuris.com Web www.mc-services.eu </pre> --------------------------------------------------------------------------- 23.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- 494833 23.08.2016
DGAP-News: AiCuris Topical Pritelivir, a Highly Active
Top 10 Most Recent News Articles
Industrial Air Compressors: Fix, Rebuild, or Replace
A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...
Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display
A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...
Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real
GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...
Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net
Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...
Continue Reading
Six LIFE Photographers Bring History Into Florida Focus
Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...
Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test
China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...
Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap
Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...
Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus
A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...
Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors
An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...
Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached
Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...
Continue ReadingTop 5 Most Recently Viewed Articles
AlidaBio Unveils New Platform to Revolutionize RNA Research
Introducing the EpiPlex™ Platform Alida Biosciences, known for its innovative tools in epigenomic research, has officially launched its EpiPlex™ platform. This groundbreaking technology stands out by being the first to detect and quantify multiple RNA modifications concurrently, using short-read sequencing. Alongside this platform, the company has introduced the...
Continue Reading
Kootenay Silver Welcomes Ron Miller to Its Board of Directors
Kootenay Silver Welcomes Ron Miller to Its Board of Directors Kootenay Silver Inc. (TSXV: KTN) (OTCQX: KOOYF) proudly announces the appointment of Ron Miller as a new director. With over 30 years of rich experience in public accounting and the mining industry, Mr. Miller brings a wealth of expertise to the company. Previously, he was a Partner and National Leader in...
Continue Reading
Estee Lauder Options Trading Insights and Market Position
Unusual Options Activity for Estee Lauder Cos Recently, a noticeable shift has occurred in the options trading landscape for Estee Lauder Cos (NYSE: EL). Our analysis has identified some significant bearish actions from prominent financial investors targeting this beauty giant. Out of a thorough review of options trading history for Estee Lauder Cos, a total of ten...
Continue Reading
Roche's Innovative PCR Test Enhances Vaginitis Diagnosis for Women
Roche Introduces Groundbreaking PCR Test for Vaginitis Roche has recently launched an innovative PCR test aimed at enhancing the diagnostic accuracy for women dealing with vaginitis. This new assay, named cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis), harnesses the power of advanced molecular technology to identify specific bacteria and yeast linked to these...
Continue Reading
Regan Capital Offers New Fee Structure for Income Fund Investment
Regan Capital Announces Fee Reduction for Its Income Fund Regan Capital, a prominent investment firm overseeing more than $2.2 billion in assets, has made a significant announcement that is sure to capture the attention of investors. The firm revealed a fee reduction for its acclaimed Regan Total Return Income Fund, known by its ticker RCIRX. This open-ended mutual fund...
Continue Reading